The effect of 17β-estradiol at doses of 0.5, 1 and 2 mg Compared with placebo on early postmenopausal bone loss in hysterectomized women

Osteoporosis International

Volumn 13, Issue 4, 2002, Pages 309-316

  Giske, L E ^a   Hall, G ^b   Rud, T ^a   Landgren, B M ^b  

^a Osteoporoselaboratoriet   (Norway)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

17 estradiol; Lumbar spine; Osteoporosis; Trochanter; Ward's triangle; Women hysterectomized

Indexed keywords

ESTRADIOL; PLACEBO; BIOLOGICAL MARKER; CREATININE; OSTEOCALCIN; PYRIDINIUM DERIVATIVE;

ADULT; ARTICLE; BONE ATROPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; HIP; HUMAN; HYSTERECTOMY; LUMBAR SPINE; MAJOR CLINICAL STUDY; OVARIECTOMY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; BONE DENSITY; DRUG ADMINISTRATION; FEMUR; LUMBAR VERTEBRA; MIDDLE AGED; URINE;

BIOLOGICAL MARKERS; BONE DENSITY; CREATININE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; FEMALE; FEMUR; FEMUR NECK; HUMANS; HYSTERECTOMY; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PYRIDINIUM COMPOUNDS;

EID: 0036012845     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200031     Document Type: Article

References (24)

1. Consensus development conference: Prophylaxis and treatment of osteoporosis
2. How many women have osteoporosis?
3. Estrace vs Premarin for treatment of menopausal symptoms: Dosage comparison study
4. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women
5. Five years with continuous combined oestrogen/progestogen therapy: Effects on calcium metabolism, lipoproteins, and bleeding patterns
6. Effect of 10 years hormone replacement therapy on bone mineral content in postmenopausal women
7. Long-term effects of percutaneus estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women
8. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
9. Hormone replacement therapy and the risk of first hip fracture: A prospective, population-based cohort study
10. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: A two-year placebo-controlled trial
11. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: Results of the Danish Osteoporosis Prevention Study
12. Increased risk of endomtrial carcinoma among users of conjugated estrogens
13. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen
14. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies
15. Immunoassay for quantifying type I collagen degradation products in urine evaluated
16. Total urinary hydroxyproline determined with raid and simple high-performance liquid chromatography
17. Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol
18. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women
19. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women
20. Effect of transdermal 17β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause
21. The minimum effective dose of estrogen for prevention of postmenopausal bone loss
22. Serum crosslinks for monitoring the response in individuals undergoing antiresorptive therapy
23. Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: Do they exist?
24. Identification of early postmenopausal women with no bone response to HRT: Results of a five-year clinical trial